Biopharmaceutical company Dizal Pharmaceutical (SSE: 688192) announced on Monday that it will showcase new clinical data for its investigational therapies DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting advancements in B-cell non-Hodgkin lymphomas (B-NHLs) and non-small cell lung cancer (NSCLC).

DZD8586, a first-in-class non-covalent LYN/BTK dual inhibitor with full blood-brain barrier penetration, achieved an objective response rate of 84.2% in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients in a pooled analysis of two Phase I/II studies. Durable response was observed across various resistance mutations, with a 9-month duration of response rate at 83.3%.

An additional Phase II study in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) demonstrated promising anti-tumour activity at 50 mg and 75 mg doses, with responses in both germinal centre B-cell-like and non-GCB subtypes. Updated data will be presented at the 2025 European Hematology Association Congress.

DZD6008, a fourth-generation, BBB-penetrant EGFR tyrosine kinase inhibitor, showed encouraging activity in pretreated EGFR-mutant NSCLC patients in the ongoing Phase I/II TIAN-SHAN2 study. As of 31 March 2025, partial responses were observed from ≥20 mg dose levels, with tumour shrinkage in 83.3% of patients. The compound demonstrated robust central nervous system exposure, with CSF/plasma drug concentration ratios exceeding 1.0.

Both agents are designed to address resistance mechanisms that limit current treatment efficacy in hematologic malignancies and lung cancer. Dizal continues to advance its global pipeline, with lead assets already launched in China.